MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 157 filers reported holding MERSANA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $82,591 | -35.0% | 65,032 | +68.4% | 0.00% | – |
| Q2 2023 | $127,047 | -5.8% | 38,616 | +17.7% | 0.00% | – |
| Q1 2023 | $134,853 | -30.8% | 32,811 | -1.4% | 0.00% | – |
| Q4 2022 | $194,980 | -94.9% | 33,273 | -94.1% | 0.00% | -100.0% |
| Q3 2022 | $3,795,000 | +2711.1% | 561,274 | +1822.8% | 0.00% | – |
| Q2 2022 | $135,000 | +12.5% | 29,190 | -2.9% | 0.00% | – |
| Q1 2022 | $120,000 | -35.1% | 30,068 | +1.2% | 0.00% | – |
| Q4 2021 | $185,000 | -38.9% | 29,718 | -7.7% | 0.00% | – |
| Q3 2021 | $303,000 | -17.7% | 32,211 | +19.1% | 0.00% | – |
| Q2 2021 | $368,000 | -94.5% | 27,045 | -93.4% | 0.00% | -100.0% |
| Q1 2021 | $6,670,000 | -81.2% | 412,170 | -69.0% | 0.00% | -80.0% |
| Q4 2020 | $35,407,000 | +70.2% | 1,330,589 | +19.1% | 0.01% | +42.9% |
| Q3 2020 | $20,806,000 | -9.5% | 1,117,416 | +13.7% | 0.01% | -12.5% |
| Q2 2020 | $22,998,000 | – | 982,795 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 796,458 | $14,830,000 | 12.35% |
| Consonance Capital Management LP | 3,468,171 | $64,577,000 | 7.87% |
| Sarissa Capital Management LP | 2,837,000 | $52,824,000 | 6.22% |
| Bain Capital Life Sciences Investors, LLC | 3,445,667 | $64,158,000 | 5.98% |
| Ghost Tree Capital, LLC | 1,050,000 | $19,551,000 | 5.65% |
| NEA Management Company, LLC | 5,959,520 | $110,966,000 | 4.70% |
| Soleus Capital Management, L.P. | 393,041 | $7,318,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 667,500 | $12,429,000 | 3.38% |
| Avoro Capital Advisors LLC | 6,800,000 | $126,616,000 | 1.80% |
| FNY Investment Advisers, LLC | 199,800 | $3,720,000 | 1.57% |